© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Back in the early 1990s, even before anyone dreamed about rapid viral diagnostics, scientists faced a hard battle against stubborn viral infections. Cidofovir came to the scene as a new line of defense against viruses that overwhelmed standard immune responses in patients with weakened systems, especially AIDS sufferers fighting cytomegalovirus retinitis. At that time, many antiviral drugs faltered, either from resistance or harsh toxic side effects. Pharmaceutically, cidofovir’s development didn’t just mean another molecule on the shelf; it helped patients actually keep their eyesight longer. This new drug, later formulated as cidofovir dihydrate for stability and handling, opened a door for modern antivirals by providing a backbone to the class of nucleotide analogs. What stands out in this history is resilience — for both the scientists who tweaked and perfected it, and the patients whose lives hung in the balance, yearning for something that worked when the usual regimen failed.
Talking about cidofovir dihydrate feels personal to folks dealing with some of medicine's nastiest viruses. The compound itself, a white to slightly off-white crystalline powder, dissolves easily in water. In practice, it’s most often used in solution form for intravenous treatment. Its correct dosing isn't just about science: for many patients, the difference between therapy and toxicity comes down to exact milligrams. For pharmacists and clinicians, each vial of cidofovir stands as both lifeline and responsibility. The pharmaceutical packaging carries just as much weight, since mislabeling or dosing errors draw hard lessons — in front-line experience, there’s no room for guesswork.
Cidofovir dihydrate comes with a distinct set of chemical traits that pharmacists and chemists learn to respect. With a molecular formula of C8H14N3O6P•2H2O, this drug’s crystalline form hides stability challenges: without proper storage, moisture or light can degrade its quality. Its solubility in water, moderate acidity (pKa near 2.8 for the phosphate group), and stable bond configuration underscore the importance of consistent, regulated storage. No one in the lab enjoys dealing with a surprise — and old hands know how changes in temperature or humidity can mess with purity and potency. For research teams, even a small dip in quality can mean the difference between a viable reaction and wasted materials.
Drug standards set by the United States Pharmacopeia and similar councils around the globe give cidofovir strict boundaries for purity and concentration. A typical vial contains exactly labeled contents, often 75 mg/mL, with strict instruction to keep away from light, refrigerate, and dilute only immediately before use. Batch records often get checked two or three times before the vial hits the clinic. The packaging must carry warnings, dosing instructions, and safe handling advice. For anyone working in a hospital pharmacy, the sight of these labels serves as a reminder: this isn’t a “casual” medicine, and vigilance matters at every step.
Making cidofovir dihydrate starts with a multi-step chemical process grounded in organic synthesis. The core route takes a protected cytosine base, links it to a propenyl group through a phosphonate connection, and carefully manages reaction conditions to prevent byproducts. The last steps involve hydration — transforming anhydrous cidofovir to the more stable dihydrate. At the benchtop or in an industrial reactor, every step calls for skilled hands, not just a recipe. Problems with impurity profiles or incomplete conversion can upend an entire batch. For manufacturing, this isn’t the time to cut corners, and overseeing each stage takes real-world persistence and keen troubleshooting.
The cidofovir structure leaves itself open to functionalization, especially at the phosphonate end and the nucleobase. Chemists have tried everything to tweak oral bioavailability, improve tissue targeting, and reduce dose-limiting kidney toxicity. Several prodrug strategies focus on masking the charged phosphonate, either through esterification or conjugation with lipid moieties — aiming to help cidofovir sneak across cell membranes. Some attempts produce analogs with longer half-lives or altered selectivity, but translating a test tube win into usable clinical products doesn’t come easy. Each new modification needs real-world experiments, not just theory; what looks promising in vitro sometimes disappoints in animals or people.
To anyone working in research or hospitals, cidofovir often goes by other names: Vistide is the trademarked formulation approved by the FDA. Chemical catalogs list it under names like (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine or HPMPC. Some researchers just call it “CDV” for convenience, while regulatory filings stick to the IUPAC nomenclature. Recognizing these different names helps avoid confusion, especially for those switching between different sources or reading international studies. I've seen paperwork thrown out over a missing synonym — another case where experience pays off.
Using cidofovir dihydrate means taking safety seriously. This isn’t just about slipping on gloves and a lab coat—direct exposure can cause severe irritation or kidney harm. Occupational protocols demand chemical splash goggles, protective clothing, and safety cabinets for weighing and transferring. Disposal rules mean no pouring leftovers down the drain; regulated hazardous waste handling keeps communities safe. Clinics administering the drug require diligent records and rigorous patient monitoring, especially with potential nephrotoxicity. I’ve watched experienced pharmacists double-check hydration plans and adjust for patient baseline kidney function, showing how critical operational care is for patient safety.
Clinically, cidofovir helped shape the antiviral landscape by providing a defense for immunocompromised patients with CMV retinitis, especially during the 1990s HIV/AIDS crisis. It comes in handy off-label for poxviruses, certain adenovirus infections, and even some emerging viral threats. Hospitals rely on it for rare cases where other antivirals don’t do the trick. Beyond medicine, research teams use cidofovir to explore virus replication and develop animal models for antiviral testing. In my own hands-on lab experience, it serves as a solid control, giving experiments a measure of reliability when assessing the potency of next-generation drugs.
Since its first approval, ongoing research keeps pushing the boundaries of what cidofovir and its analogs can offer. Lab teams now focus on oral formulations, encapsulation in nanoparticles, and targeted delivery systems to lower the risk of kidney harm. Animal models steadily inform dosing strategies and suggest new combinations with other antivirals. Surveillance of resistance also shapes future research goals: viral mutations that dodge cidofovir pressure don’t show up as fast as with other drugs, but careful monitoring remains crucial. Collaboration between academic labs, pharmaceutical companies, and regulatory agencies helps keep innovation on track, reflecting lessons hard-won on both the bench and the bedside.
Anyone who’s tracked cidofovir’s medical history knows kidney toxicity stands out as its single greatest drawback. Pre-medication with probenecid and intravenous hydration greatly reduce the risk, but researchers continue to dig for mechanisms behind the nephrotoxic effects. Studies highlight uptake by organic anion transporters in the kidney as a culprit. Some teams work on transporter blockers, others design analogs or prodrugs less likely to trigger kidney problems. Rigorous animal safety studies guide dosing, administration intervals, and pilot trials, keeping clinical use as safe as possible. Patient stories give extra motivation to find solutions — keeping people healthy shouldn’t come at the cost of losing kidney function.
Cidofovir dihydrate’s story isn’t stuck in the last century. Scientists now explore next-generation delivery systems, including lipid nanoparticles and implantable devices, to achieve sustained release with fewer side effects. The ongoing drive to repurpose and modify cidofovir for emerging viral outbreaks holds real promise, especially in a world facing unexpected new threats. Development of better-tolerated analogs, broader-spectrum options, and easier routes of administration keeps cidofovir relevant for both clinicians and chemists. Integrating old lessons with new technologies — artificial intelligence in drug design, advanced imaging for tracking distribution — gives hope for safer, more effective treatments down the line. In real practice and research, cidofovir’s journey tells a story of grit, adaptation, and patients’ voices guiding innovation.
Hospitals and clinics often deal with viral infections that don’t respond well to standard treatments. Cidofovir dihydrate steps in as a real solution for people with immune systems that struggle to keep these viruses at bay. Physicians often reach for this medicine when facing cytomegalovirus retinitis, especially in patients already battling conditions like HIV/AIDS. Left untreated, CMV retinitis can steal sight in a matter of months. I’ve witnessed the fear in patients’ eyes when vision starts to fade. In those tense moments, cidofovir dihydrate is often one of the last lines standing between disease and permanent loss.
The world has wrestled with countless viruses, but some refuse to budge using basic antivirals. Take cytomegalovirus, a name that few people had heard until immunocompromised individuals began losing vision or, in some cases, their lives. Cidofovir dihydrate helps put a stop to this virus’ rampage within the eyes, especially for people whose immune systems have been battered by other illnesses. I don’t forget the gratitude in a patient’s voice when their sight stabilizes after a course of treatment—there’s relief, hope, and sometimes even disbelief that something as small as an injection could help so much.
The drug throws itself into the viral DNA replication process and causes the virus to stumble. Instead of letting the virus multiply, cidofovir gets in the way and halts the whole operation. Viruses like to be sneaky, mutating or hiding from other drugs, but cidofovir can tackle many strains that don’t fall easily. Researchers noticed its broad effect against different DNA viruses, which sets it apart from treatments that work on just one or two viral types.
Even the strongest medicines bring risks. Kidney toxicity stands at the top of the list with cidofovir dihydrate. Every dose asks for careful monitoring. Patients must drink plenty of fluids and often receive another medication, probenecid, to protect the kidneys. On one hand, I’ve seen patients regain function and comfort thanks to this drug; on the other, I’ve watched teams scramble to manage side effects. That’s the constant tension with powerful treatments: relief comes at a cost, sometimes measured in anxious bloodwork and long infusion sessions. Doctors and nurses put in extra effort, watching not just for improvement in the disease but also for signs of kidney trouble or eye inflammation.
Researchers stay hard at work looking for safer antivirals, but cidofovir dihydrate shows practical value for people without alternatives. Hospitals in areas where resistant viruses hit hardest still use this medicine, sometimes in new ways—like exploring its effects on adenovirus infections or even rare poxviruses. Learning from each case, the medical world adapts dosing, tries different combinations, and shares knowledge across borders. My own experience reminds me medicine never stands still. Nurses and doctors share war stories about tricky cases and lifesaving recoveries. Cidofovir dihydrate stands as both a warning and a lifeline: handle with care, use with compassion, and never forget the patient behind every diagnosis.
Finding less toxic alternatives starts with honest conversations between clinicians, patients, and pharmacists. Recognizing the real risks and setting realistic goals go a long way. In many teaching hospitals, pharmacists lead training on proper infusion techniques and side effect monitoring, making safer care more likely. With new research coming in from all corners of the globe—thanks to greater data sharing and collaboration—safer, more effective working solutions seem closer than ever. Until that day, cidofovir dihydrate keeps playing its part in the effort to help those who’ve run out of options. For anyone looking at a diagnosis of CMV retinitis or another stubborn viral infection, knowing this medicine exists can mean the difference between hope and despair.
Cidofovir Dihydrate often ends up in treatment plans for tough viral infections, especially when other options can’t cut it. Used mostly for cytomegalovirus (CMV) retinitis in people with HIV, it has been known to bring hope for sight. Despite these benefits, it comes with several risks that deserve open discussion. I’ve come across patients who needed this antiviral punch, and each one grappled with trade-offs. No one signs up for medicine wanting trouble—so it pays to know what might show up once treatment begins.
Doctors don’t hand out Cidofovir lightly. The most feared side effect is kidney damage. I’ve seen entire care teams hold their breath after just a few infusions, watching lab results like hawks. Tubular necrosis and a jump in creatinine are real possibilities, and these can lead to outright kidney failure. The drug can be hard on the kidneys because it filters through them, sometimes leaving lasting damage. Hydration and probenecid usually get added to the routine for anyone starting treatment, because failing to protect the kidneys can spell disaster.
Low white blood cell counts, or neutropenia, often creep in quietly. Folks battling CMV don’t need another shot to the immune system. These drops make the threat of infections much more real. Throughout my years working with such patients, we checked blood counts often to catch dips early and discuss if it was safe to keep going with treatment.
Friends and family expect Cidofovir to hold off blindness from CMV eye disease, but sometimes the very drug given to protect vision stirs up trouble. Uveitis and eye inflammation can show up, leaving patients with redness, pain, and light sensitivity. In rare cases, these symptoms tip over into vision loss. Those on Cidofovir need rapid attention for eye problems, or small complaints could turn into big regrets.
Regular office visits often catch other surprises—fevers, headaches, nausea, rashes, or even hair loss. Such problems range from annoying to reasons for stopping treatment. Allergic reactions can happen, sometimes with breathing problems. Some people develop protein in their urine, which sometimes signals brewing kidney damage.
Cidofovir still finds a place in fighting difficult viral illnesses, especially where nothing else works. At the same time, no one should take it without close medical supervision. People on it should expect regular lab checks and honest conversations with their doctors about tradeoffs. Probenecid lowers kidney risk, and hydration helps, too. Sometimes doctors call in other treatments when risks get out of hand.
Cidofovir’s side effects tip the scales for those already battling major illness. I’ve watched people share their concerns with loved ones, weighing every treatment decision carefully. Open communication about the drug’s risks, regular monitoring, and preparation for treating side effects matter more than any brochure or instruction list. As research and experience with antivirals stack up, the lessons learned from these risks will push care forward—and maybe, in time, bring safer alternatives for those who need help most.
Cidofovir Dihydrate isn’t one of those medicines you just pick up at the pharmacy and take at home. It enters the line-up mostly for people battling serious viral infections like cytomegalovirus (CMV) retinitis, which often strikes people with weakened immune systems. Doctors don’t hand this out lightly, and not just any clinic handles it. Most of the time, hospitals or clinics set up the infusion, and patients stick around long enough for a solid watch to make sure their body copes with the powerful punch of the medicine.
Delivery comes through an intravenous infusion. That means the drug runs straight into a vein, mixed with sterile saline, usually over the course of about an hour. For someone living with a suppressed immune system and dealing with tough infections, skipping or skipping steps—or trying shortcuts—just isn’t in the cards. Before each dose, patients hydrate with fluids and take an oral medicine called probenecid in advance and afterward. Doctors use probenecid because it helps reduce the chance of kidney damage, a known risk with cidofovir.
In my experience writing about complicated medicines and talking with patients and caregivers, fear of the side effects often keeps people up at night. The steps involved in cidofovir’s administration—hydrating well beforehand, checking kidney function with blood tests, pairing with probenecid—aren't just arbitrary hoops. A friend of mine once had to weigh powerful antivirals like this after a transplant, and the anxiety around “will it hurt my kidneys?” shaped every hospital visit. Cidofovir can mess with kidney function and even cause vision changes, so sticking to a plan isn’t about checking boxes; it’s about protecting organs for the long haul.
Anyone facing this medication, or supporting someone who is, benefits from asking about fluid intake, symptom monitoring, and early signs of trouble. People sometimes underrate the power of staying hydrated and watching for subtle shifts in urine or eyesight. Family members often help keep a watchful eye, especially since fatigue and illness blur the details. One family I interviewed made a chart for tracking fluids and symptoms, which became as vital as the medication itself.
Access to specialists, regular lab testing, and the support needed to follow this regimen can make things harder for folks who live far from medical centers or who struggle with transportation and time away from work. Telehealth consults, home health visits for labs or hydration purposes, and better insurance coverage for supportive medicines like probenecid could make a real difference. A system that covers frequent testing and provides transportation support lightens the load when bodies are at their most vulnerable.
Navigating cidofovir dihydrate treatment depends on clear communication. Healthcare teams must explain side effects, safety steps, and the reasoning behind each precaution. Patients and caregivers deserve the facts, not just instructions. By weaving honesty, support, and practical safety measures together, care teams and families can make this tough experience more manageable—right down to each monitored drop of medicine running through that IV.
Cidofovir Dihydrate comes with a sharp double edge. On one side, it offers hope against certain viral infections, especially for people whose immune systems feel overwhelmed or who have run into viruses that don’t listen to other drugs. On the other side, using this antiviral without respect for its risks can hurt the kidneys and trigger other unwanted problems. This isn’t a simple painkiller; this is a medication for serious cases.
The biggest issue with cidofovir centers on kidney safety. I’ve seen patients who needed antivirals but had to stop suddenly because their kidney numbers took a nosedive. Doctors ask for pre-treatment blood work, and they won’t skip it. Strict hydration before each infusion helps cushion the kidneys. A doctor will probably suggest probenecid alongside cidofovir because it blocks the medicine’s toxic effect on the kidneys. This drug combination demands close monitoring — not just at the first visit, but each time the medicine goes in.
People with allergies or past reactions to cidofovir must come clean about it early. Even one bad experience counts. For those on other medicines, particularly those that strain the kidneys or suppress the immune system, doctors have to weigh every pill and injection. Overlapping with other nephrotoxic agents compounds the risk. Common sense says you can’t let cidofovir join a list of drugs without careful review.
You’ll hear nurses and doctors talk about timing and dosages. Following this schedule isn’t a suggestion. Blood tests come before and after each dose. These numbers tell the whole story: how well the kidneys are working, whether there’s bone marrow suppression, or if there’s a risk of electrolyte imbalance. If there’s evidence of white blood cells dropping or changes in eyesight, it’s not enough to “keep an eye on it.” The care team has to act quickly.
Cidofovir can bother the eyes. If something feels off — blurry vision, eye pain — that call to an ophthalmologist can’t wait. Semen and urine may carry drug residues for some time. For people wanting to start a family, discussing fertility concerns before treatment ensures all choices stay on the table. Everyone in the room, from medical staff to family members, should respect the risk and avoid direct contact with the medicine or patient’s bodily fluids, at least until given the clear by a knowledgeable physician.
No two people respond to medicines the same way. Honest talk between patient and care team means problems get flagged before they turn to emergencies. Trusted online medical sources and open lines of communication keep everyone sharp about dosage, test results, side effects, and infection warning signs. Families can help remind each other about hydration steps, checkups, and symptoms worth reporting. Every safeguard protects not just one person, but everyone responsible for their care.
Cidofovir Dihydrate shows up mostly in the treatment of viral infections, especially for patients with weakened immunity. I remember meeting someone who needed this medication because their immune system couldn’t keep certain viruses in check. The potential for interaction with other drugs isn’t just theoretical talk—it can cause real physical effects and setbacks for people facing serious health conditions.
Cidofovir works by slowing down how some viruses multiply inside the body. This job can put stress on the kidneys, a concern already known to many. The kidneys break down or clear away a lot of medicines. When two or more drugs compete for the same process, the risk for one or both drugs to build up increases. This can end up causing more harm than intended.
Probenecid often gets prescribed alongside cidofovir. It isn’t a random add-on; probenecid helps shield the kidneys by slowing cidofovir’s passage into those organs. At the same time, this combination can make the kidneys work harder to clear away other medicines in the system. For people who already get other treatments — say, for blood pressure, diabetes, or sleep — this steady rise in risk feels very real.
Polypharmacy jumps to mind here. Many older folks and those with chronic health problems juggle three, five, sometimes more prescriptions. Cidofovir’s risk of kidney damage doesn’t mix well with medicines like NSAIDs, which many people use for pain. Diuretics pose a similar risk. Some chemo drugs also stress the kidneys, so stacking them with cidofovir needs careful monitoring.
I’ve seen care teams come together to evaluate every pill a patient takes once cidofovir enters the mix. It’s not a small task. Each prescription, each supplement, and even certain herbal remedies bring another layer of risk. The body doesn’t recognize medical boundaries; it only knows there’s more work to do.
Doctors need accurate lists of medications, including over-the-counter and “natural” remedies. Patients sometimes forget to mention a daily aspirin or a familiar supplement, but these can change the way cidofovir moves through the body. Pharmacists play their part by tracking new interactions. Electronic records help, but alert fatigue can set in—sometimes critical warnings get lost in information clutter.
Blood tests—like serum creatinine—offer a way to keep tabs on kidney function. I’ve watched doctors order these before every cidofovir use, aiming to catch kidney strain as soon as possible. Dose adjustments, spacing out treatments, or switching to safer drug plans all come from having current lab results.
Education goes a long way. Patients aware of the signs of kidney trouble—lower urine output, swelling in the legs, changes in thinking—can get help quickly. Providers who take time to explain what to watch for and why it matters can catch problems before they grow.
Research keeps reinforcing what front-line staff see every day: drug interactions aren’t just footnotes in a textbook. Cidofovir ranks near the top of medications with a meaningful risk of kidney toxicity. The FDA and medical journals urge caution, especially for people with weak kidneys or those using other high-risk meds.
Serious infections need powerful tools, and cidofovir gives hope, but its risks must stay visible. Thoughtful prescribing, full communication, and ongoing checks form a safety net for those who need this medicine most.
| Names | |
| Preferred IUPAC name | (2R)-1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine;dihydrate |
| Other names |
Vistide CDV HPMPC Cidofovir Monohydrate Cidofovir hydrate |
| Pronunciation | /saɪˈdoʊfəˌvɪər daɪˈhaɪdreɪt/ |
| Identifiers | |
| CAS Number | 202140-95-7 |
| 3D model (JSmol) | `load = /pub/chem3d/PubChem/63150.mol` |
| Beilstein Reference | 4122531 |
| ChEBI | CHEBI:34755 |
| ChEMBL | CHEMBL1200961 |
| ChemSpider | 21545137 |
| DrugBank | DB00369 |
| ECHA InfoCard | 03cc34da-3b5a-4005-ae10-6fd6f1a4b072 |
| EC Number | 206-331-3 |
| Gmelin Reference | 104782 |
| KEGG | D03624 |
| MeSH | Dioxolane Derivatives |
| PubChem CID | 44144497 |
| RTECS number | GQ8495000 |
| UNII | ZIY9T6S2C8 |
| UN number | 3464 |
| Properties | |
| Chemical formula | C8H14N3O6P·2H2O |
| Molar mass | 389.22 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Soluble in water |
| log P | -2.0 |
| Acidity (pKa) | 3.3 |
| Basicity (pKb) | pKb = 2.8 |
| Magnetic susceptibility (χ) | -8.8e-6 cm^3/mol |
| Dipole moment | 2.74 D |
| Pharmacology | |
| ATC code | J05AB12 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye damage. May cause genetic defects. May cause cancer. Causes damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H360FD, H301, H331, H373 |
| Precautionary statements | P260, P262, P280, P301+P310, P302+P352, P305+P351+P338, P308+P313 |
| Lethal dose or concentration | Lethal dose or concentration (LD50): ">2000 mg/kg (rat, oral) |
| LD50 (median dose) | > 370 mg/kg (Rat, intravenous) |
| NIOSH | Not listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 10 mg/mL |
| Related compounds | |
| Related compounds |
Cidofovir Brincidofovir Adefovir Tenofovir Ganciclovir |
